ATE300314T1 - Zusammensetzung und verfahren zur immunisierung gegen ein oder mehrere antigene mittels verschiedener rekombinanter vektoren - Google Patents

Zusammensetzung und verfahren zur immunisierung gegen ein oder mehrere antigene mittels verschiedener rekombinanter vektoren

Info

Publication number
ATE300314T1
ATE300314T1 AT00904124T AT00904124T ATE300314T1 AT E300314 T1 ATE300314 T1 AT E300314T1 AT 00904124 T AT00904124 T AT 00904124T AT 00904124 T AT00904124 T AT 00904124T AT E300314 T1 ATE300314 T1 AT E300314T1
Authority
AT
Austria
Prior art keywords
antigens
composition
recombinant vectors
immunization against
different recombinant
Prior art date
Application number
AT00904124T
Other languages
English (en)
Inventor
Jonathan Luke Heeney
Original Assignee
Stichting Biomedical Primate R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8239845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE300314(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stichting Biomedical Primate R filed Critical Stichting Biomedical Primate R
Application granted granted Critical
Publication of ATE300314T1 publication Critical patent/ATE300314T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT00904124T 1999-01-28 2000-01-28 Zusammensetzung und verfahren zur immunisierung gegen ein oder mehrere antigene mittels verschiedener rekombinanter vektoren ATE300314T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200256 1999-01-28
PCT/NL2000/000058 WO2000044410A2 (en) 1999-01-28 2000-01-28 Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors

Publications (1)

Publication Number Publication Date
ATE300314T1 true ATE300314T1 (de) 2005-08-15

Family

ID=8239845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00904124T ATE300314T1 (de) 1999-01-28 2000-01-28 Zusammensetzung und verfahren zur immunisierung gegen ein oder mehrere antigene mittels verschiedener rekombinanter vektoren

Country Status (8)

Country Link
US (2) US6783762B1 (de)
EP (1) EP1144014B1 (de)
AT (1) ATE300314T1 (de)
AU (1) AU2579600A (de)
CA (1) CA2361353A1 (de)
DE (1) DE60021523T2 (de)
ES (1) ES2246826T3 (de)
WO (1) WO2000044410A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0935659A1 (de) 1996-09-17 1999-08-18 Chiron Corporation Zusammensetzungen und verfahren zur behandlung intrazellulärer erkrankungen
US20050208020A1 (en) * 2003-11-12 2005-09-22 Doolan Denise L Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511845B1 (en) * 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US5752075A (en) * 1993-02-10 1998-05-12 Elonex Plc, Ltd. Integrated computer Scanner printer in a single system enclosure sharing control circuitry and light source wherein a single CPU performing all of the control tasks
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
AU2678797A (en) * 1996-04-22 1997-11-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Heterologous boosting immunizations
CA2269754A1 (en) * 1996-10-23 1998-04-30 American Home Products Corporation Dna vaccines for herpes simplex virus 1 and 2
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO2000011140A1 (en) * 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting

Also Published As

Publication number Publication date
US20050002967A1 (en) 2005-01-06
CA2361353A1 (en) 2000-08-03
US6783762B1 (en) 2004-08-31
DE60021523D1 (de) 2005-09-01
DE60021523T2 (de) 2006-06-22
WO2000044410A3 (en) 2000-12-07
EP1144014A2 (de) 2001-10-17
ES2246826T3 (es) 2006-03-01
WO2000044410A2 (en) 2000-08-03
EP1144014B1 (de) 2005-07-27
AU2579600A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
ATE411043T1 (de) Verfahren von dna-impfung
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
WO2002080851A3 (en) Chimeric vaccines
DE69734601D1 (de) Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
NO20081043L (no) Vaksine for fisk
WO2009154995A3 (en) Interleukin 10 receptor (il-10r) antibodies and methods of use
DE69723434D1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
KR890701125A (ko) 무병원성 미생물 및 이의 용도
IS7601A (is) Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum
RU2014124923A (ru) Рекомбинантные белки и их применения в терапевтических целях
BR0111823A (pt) Polipeptìdeo, vacina, método para imunizar um animal contra um micróbio patogênico, método para identificar polipeptìdeo antigênicos, anticorpo, ou pelo menos uma parte eficaz deste, vetor, célula, método para a produção do anticorpo, linhagem celular de hibridomas, e, uso dos anticorpos.
EP0855918A4 (de) Interleukin-15 aus hühnern und seine verwendungen
MXPA01011047A (es) Secuencias genomicas de neisseria y metodos para su uso.
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
BR9809656A (pt) Composição imunopotencializante
DE60310562D1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
WO2005007673A3 (en) Immunogenic peptides
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
RU2015107435A (ru) Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
DK1446422T3 (da) Methyleret, rekombinant, mykobakterielt antigen af typen heparinbindende hæmagglutinin
DE69520943D1 (de) Malariapeptide
WO2009074861A3 (en) Improved vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties